Exelixis Reports Q1 2026 Earnings with Strong Cabozantinib Performance
Exelixis reported Q1 2026 earnings with total revenues of $611 million, driven by strong performance from its cabozantinib franchise. The U.S. cabozantinib franchise saw an 8% year-over-year increase in net product revenues to $555 million, while global revenues rose 12.5% to $764 million. Operating expenses decreased slightly to $359 million.
Tickers: $EXEL
Topics: drug_sales financials pharmaceuticals revenue